Addex Therapeutics Ltd (ADXN.SW)
CHF 0.06
(-1.34%)
CHF 0.06
(-1.34%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -5.31 Million CHF | 59.71% |
| 2022 | -13.2 Million CHF | -33.31% |
| 2021 | -9.9 Million CHF | -46.47% |
| 2020 | -6.76 Million CHF | -366.92% |
| 2019 | 2.53 Million CHF | -57.07% |
| 2018 | 5.89 Million CHF | 1154.91% |
| 2017 | 470.13 Thousand CHF | 0.0% |
| 2016 | - CHF | 0.0% |
| 2015 | - CHF | 0.0% |
| 2014 | - CHF | 0.0% |
| 2013 | - CHF | 100.0% |
| 2012 | -1.14 Million CHF | 95.44% |
| 2011 | -25.16 Million CHF | -1373.86% |
| 2010 | 1.97 Million CHF | -51.71% |
| 2009 | 4.09 Million CHF | -84.74% |
| 2008 | 26.8 Million CHF | 5405.28% |
| 2007 | 486.93 Thousand CHF | -89.72% |
| 2006 | 4.73 Million CHF | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 235 Thousand CHF | 117.25% |
| 2024 Q2 | 115.27 Thousand CHF | -50.95% |
| 2023 FY | -5.31 Million CHF | 59.71% |
| 2023 Q4 | -1.36 Million CHF | 8.08% |
| 2023 Q3 | -1.48 Million CHF | -19.14% |
| 2023 Q2 | -1.24 Million CHF | -3.42% |
| 2023 Q1 | -1.2 Million CHF | 91.43% |
| 2022 Q1 | -3.52 Million CHF | 71.59% |
| 2022 Q3 | -2.35 Million CHF | 57.67% |
| 2022 FY | -13.2 Million CHF | -33.31% |
| 2022 Q2 | -5.56 Million CHF | -57.69% |
| 2022 Q4 | -14.03 Million CHF | -495.73% |
| 2021 Q1 | -1.9 Million CHF | -171.22% |
| 2021 FY | -9.9 Million CHF | -46.47% |
| 2021 Q2 | -2.73 Million CHF | -43.88% |
| 2021 Q3 | 682 Thousand CHF | 124.9% |
| 2021 Q4 | -12.42 Million CHF | -1921.26% |
| 2020 FY | -6.76 Million CHF | -366.92% |
| 2020 Q4 | -701.95 Thousand CHF | 64.03% |
| 2020 Q3 | -1.95 Million CHF | -33.84% |
| 2020 Q2 | -1.45 Million CHF | -272.3% |
| 2020 Q1 | 846.32 Thousand CHF | 132.82% |
| 2019 Q3 | -2.41 Million CHF | -628.05% |
| 2019 Q1 | 660.01 Thousand CHF | 207.17% |
| 2019 FY | 2.53 Million CHF | -57.07% |
| 2019 Q4 | -2.57 Million CHF | -6.88% |
| 2019 Q2 | 456.82 Thousand CHF | -30.79% |
| 2018 FY | 5.89 Million CHF | 1154.91% |
| 2018 Q3 | -749.85 Thousand CHF | -145.67% |
| 2018 Q2 | 1.64 Million CHF | 0.0% |
| 2018 Q1 | 1.64 Million CHF | 371.84% |
| 2018 Q4 | -615.85 Thousand CHF | 17.87% |
| 2017 Q3 | -603.95 Thousand CHF | -31.14% |
| 2017 FY | 470.13 Thousand CHF | 0.0% |
| 2017 Q4 | -603.95 Thousand CHF | 0.0% |
| 2017 Q2 | -460.54 Thousand CHF | 0.0% |
| 2017 Q1 | -460.54 Thousand CHF | 27.62% |
| 2016 Q1 | -388.51 Thousand CHF | -503.56% |
| 2016 FY | - CHF | 0.0% |
| 2016 Q4 | -636.32 Thousand CHF | 0.0% |
| 2016 Q3 | -636.32 Thousand CHF | -63.78% |
| 2016 Q2 | -388.51 Thousand CHF | 0.0% |
| 2015 Q4 | -64.37 Thousand CHF | 0.0% |
| 2015 Q2 | -429.65 Thousand CHF | -0.0% |
| 2015 Q1 | -429.65 Thousand CHF | -171.28% |
| 2015 FY | - CHF | 0.0% |
| 2015 Q3 | -64.37 Thousand CHF | 85.02% |
| 2014 Q1 | -152.47 Thousand CHF | -122.24% |
| 2014 Q4 | -158.37 Thousand CHF | 0.0% |
| 2014 Q3 | -158.37 Thousand CHF | -3.87% |
| 2014 Q2 | -152.47 Thousand CHF | 0.0% |
| 2014 FY | - CHF | 0.0% |
| 2013 Q3 | 685.64 Thousand CHF | 114.95% |
| 2013 Q4 | 685.64 Thousand CHF | 0.0% |
| 2013 FY | - CHF | 100.0% |
| 2013 Q1 | -4.58 Million CHF | -33.72% |
| 2013 Q2 | -4.58 Million CHF | 0.0% |
| 2012 Q3 | -3.43 Million CHF | 0.0% |
| 2012 FY | -1.14 Million CHF | 95.44% |
| 2012 Q4 | -3.43 Million CHF | 0.0% |
| 2011 FY | -25.16 Million CHF | -1373.86% |
| 2010 FY | 1.97 Million CHF | -51.71% |
| 2009 FY | 4.09 Million CHF | -84.74% |
| 2008 FY | 26.8 Million CHF | 5405.28% |
| 2007 FY | 486.93 Thousand CHF | -89.72% |
| 2006 FY | 4.73 Million CHF | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| BB Biotech AG | -199.56 Million CHF | 97.335% |
| Basilea Pharmaceutica AG | 130.84 Million CHF | 104.065% |
| Evolva Holding SA | -2.58 Million CHF | -105.928% |
| Idorsia Ltd | 145.23 Million CHF | 103.662% |
| Kuros Biosciences AG | 22.87 Million CHF | 123.252% |
| Molecular Partners AG | -40.8 Million CHF | 86.967% |
| Relief Therapeutics Holding AG | -10.85 Million CHF | 51.024% |
| Santhera Pharmaceuticals Holding AG | 99.54 Million CHF | 105.343% |